This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Aug 2013

Integrated DNA Technologi?es Enhances its qPCR Probe Portfolio

Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has further expanded its portfolio of PrimeTime® qPCR products with the launch of two new probes. The PrimeTime Eco Probe and PrimeTime Mini LNA Probe complete the existing offering, providing new options for customers performing gene expression and genotyping experiments.

 

Developed to support customers looking for a cost-effective option at the mid-scale range, the Eco Probe is delivered at a normalised yield of 2.5 nmoles, sufficient for approximately 500 reactions, bridging the space between the existing PrimeTime Mini qPCR Probe (0.5 nmole normalized yield, 100 reactions) and the 100 nmole synthesis scale (minimum guaranteed yield of 10 nmoles). If ordered with the option of an internal ZEN quencher, the double-quenched PrimeTime Eco Probe will generate less background noise, while increasing end point signal, to significantly boost qPCR sensitivity and precision when compared to traditional single-quenched probes. The Eco Probe is available with a FAM/ZEN/IA Black FQ dye/quencher combination.

 

When genotyping via PCR, it is often useful to be able to perform a few reactions using a small subset of probes, in order to test and consequently optimise LNA probe design. The new PrimeTime Mini LNA Probes enable customers to do as few as 100 reactions, allowing preliminary experiments to be performed at a low initial cost.

 

Guidelines for LNA probe design are available online, under the Overview tab to aid users in their initial design. IDT can also provide full design support, if required — design fees may apply. The Mini LNA Probes join the existing 250 nmole PrimeTime LNA Probes, which provide 8000 reactions and are ideal for large-scale screening.
 

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.